-
Drugs Sep 1980Sulfinpyrazone1 has long been recognised as a potent uricosuric agent, but has more recently been studied extensively as a platelet inhibitor and antithrombotic agent.... (Clinical Trial)
Clinical Trial Review
Sulfinpyrazone1 has long been recognised as a potent uricosuric agent, but has more recently been studied extensively as a platelet inhibitor and antithrombotic agent. It is active in man following oral administration and has been reported to be effective in reducing the incidence of transient ischaemic attacks, thromboembolism associated with vascular and cardiac prostheses, recurrent venous thrombosis, arteriovenous shunt thrombosis and sudden cardiac death following myocardial infarcton. Sulfinpyrazone has not been demonstrated to be effective in preventing or reducing the risk of stroke or death in patients with cerebrovascular disease with a recent history of cerebral or retinal ischaemioc attacks. The normal total dose of sulfinpyrazone as an antithrombotic agent is 800mg daily. The drug has been used continuously for up to 4 years with no serious adverse reactions or laboratory abnormalities. There has been no apparent diminution of effect with time. Sulfinpyrazone is not a substitute for conventional anticoagulant agents (e.g. the coumarin derivatives) in the treatment of venous thrombosis, but is an important drug for the treatment of conditions associated with arterial thrombosis and possibly for the prophylaxis of recurrent venous thrombosis.
Topics: Animals; Anti-Arrhythmia Agents; Antibody Formation; Aspirin; Blood Platelets; Cardiovascular Diseases; Cerebrovascular Disorders; Clinical Trials as Topic; Fibrinolytic Agents; Humans; Platelet Aggregation; Prostaglandins; Sulfinpyrazone; Thrombosis
PubMed: 7000488
DOI: 10.2165/00003495-198020030-00002 -
Circulation Apr 1981
Topics: Coronary Disease; Humans; Sulfinpyrazone
PubMed: 7471356
DOI: 10.1161/01.cir.63.4.970 -
The Medical Journal of Australia Aug 1978
Clinical Trial
Topics: Clinical Trials as Topic; Double-Blind Method; Humans; Myocardial Infarction; Recurrence; Sulfinpyrazone
PubMed: 364265
DOI: 10.5694/j.1326-5377.1978.tb131455.x -
Thrombosis Research. Supplement 1983
Review
Topics: Blood Platelets; Dose-Response Relationship, Drug; Humans; Kinetics; Sulfinpyrazone
PubMed: 6356467
DOI: 10.1016/0049-3848(83)90363-8 -
The New England Journal of Medicine Sep 1980
Topics: Anaphylaxis; Aspirin; Asthma; Bronchial Spasm; Dipyrone; Drug Hypersensitivity; Humans; Sulfinpyrazone
PubMed: 7402260
DOI: 10.1056/nejm198009183031217 -
Advances in Pharmacology 1966
Review
Topics: Gout; Humans; Male; Probenecid; Sulfinpyrazone; Uricosuric Agents
PubMed: 5333771
DOI: 10.1016/s1054-3589(08)60098-8 -
The Medical Journal of Australia Jun 1980
Topics: Australia; Death, Sudden; Humans; Myocardial Infarction; Recurrence; Risk; Sulfinpyrazone
PubMed: 7402151
DOI: 10.5694/j.1326-5377.1980.tb135151.x -
British Medical Journal Aug 1978
Clinical Trial
Topics: Aspirin; Canada; Cerebrovascular Disorders; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Random Allocation; Sulfinpyrazone
PubMed: 354745
DOI: No ID Found -
British Medical Journal Jun 1979
Topics: Colchicine; Cortisone; Gout; Humans; Male; Probenecid; Sulfinpyrazone
PubMed: 466182
DOI: 10.1136/bmj.1.6179.1695 -
Canadian Medical Association Journal Feb 1973
Topics: Aspirin; Blood Platelets; Dipyridamole; Humans; Sulfinpyrazone; Thromboembolism
PubMed: 4687370
DOI: No ID Found